The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.
 
Julia Rotow
Honoraria - AstraZeneca; Daiichi Sankyo; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blossom Hill; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daiichi Sankyo; EMD Serono; Gilead Sciences; Johnson & Johnson/Janssen; Merus; Novocure; Nuvalent, Inc.; Nuvation Bio; Pfizer; Sanofi/Regeneron; Summit Therapeutics; Takeda
Research Funding - Abbvie (Inst); Altor BioScience (Inst); AstraZeneca (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Blossom Hill (Inst); Blueprint Medicines (Inst); Bristol-Myer Squibb; Daiichi Sankyo (Inst); DualityBio (Inst); Enliven Therapeutics (Inst); EpimAb (Inst); ImmunityBio (Inst); Loxo (Inst); ORIC Pharmaceuticals (Inst); RedCloud Biotech (Inst); Regeneron (Inst); Summit Therapeutics (Inst); Synthekine (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Black Diamond Therapeutics; BMS; Daiichi Sankyo; Johnson & Johnson/Janssen; Merus
 
Christina Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Lilly; Natera; Nuvalent, Inc.; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blossom Hills (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Summit Therapeutics (Inst); Systimmune (Inst); TP Therapeutics (Inst)
 
Anastasios Dimou
Honoraria - Intellisphere; Intellisphere (Inst); Intellisphere (Inst); Roche/Genentech
Consulting or Advisory Role - Anheart Therapeutics; ChromaCode; Guardant Health (Inst); Nuvalent, Inc. (Inst); Rigel (Inst); TP Therapeutics (Inst)
Research Funding - Anheart Therapeutics (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Guardant Health; Janssen (Inst); Merck; Novartis (Inst); Philogen (Inst); Sorrento Therapeutics (Inst); Syntrix Biosystems (Inst)
Travel, Accommodations, Expenses - Guardant Health
Other Relationship - Rising Tide Foundation (Inst)
 
Jamie Feng
Honoraria - Amgen; AstraZeneca Canada; Merck; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca Canada; Knight Therapeutics; Merck; Pfizer
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; DAVA Pharmaceuticals
 
Danny Nguyen
Honoraria - Black Diamond Therapeutics; Janssen Oncology; Taiho Pharmaceutical
Consulting or Advisory Role - Black Diamond Therapeutics; Janssen Oncology
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen; Taiho Oncology
Other Relationship - Novartis; Pfizer; Seagen; Takeda
(OPTIONAL) Uncompensated Relationships - Johnson & Johnson/Janssen; Novartis; Takeda
 
Sarah Gordon
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Nuvation Bio
 
Haobin Chen
No Relationships to Disclose
 
Aakash Desai
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bristol Myers Squibb; ConcertAI; Daichii Sankyo; Foundation Medicine; Janssen Oncology; Lilly; Merus; Regeneron; Sanofi
 
Jiaxin Niu
Consulting or Advisory Role - AstraZeneca; Bristol Mers Squibb; Daiichi Sankyo; G1 Therapeutics; Johnson & Johnson; Mirati Therapeutics; Pfizer; Sanofi; Takeda
 
Amin Benyounes
No Relationships to Disclose
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeOne Medicines (Inst); Biohaven Pharmaceuticals (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Nuvalent, Inc. (Inst); Ottimo Pharma (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Summit Therapeutics (Inst); Zai Lab (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); BlossomHill Therapeutics (Inst); Boehringer Ingelheim (Inst); Boundless Bio (Inst); Bristol-Myers Squibb (Inst); Carisma Therapeutics (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Modex Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); PMV Pharma (Inst); Prelude Therapeutics (Inst); Puma Biotechnology (Inst); RasCal (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Shanghai Junshi BioSciences (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Systimmune (Inst); Taiho Oncology (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Kamya Sankar
Consulting or Advisory Role - AstraZeneca
Research Funding - Amgen (Inst); Black Diamond Therapeutics (Inst); Genentech/Roche (Inst); Harpoon therapeutics (Inst); Lilly (Inst); Merck (Inst); Summit Therapeutics (Inst)
 
Susan Scott
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; EMD Serono; Johnson & Johnson/Janssen; Merus; Summit Therapeutics
Research Funding - Black Diamond Therapeutics (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Nuvalent, Inc. (Inst)
 
Alex Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
James Stevenson
Honoraria - MJH Life Sciences
Consulting or Advisory Role - OptumHealth
Research Funding - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Henlius (Inst); Merck Sharp & Dohme (Inst); PrECOG (Inst)
 
Shetal Patel
Consulting or Advisory Role - Astellas Pharma; Genentech; IQvia; Pharmacosmos
Research Funding - Amgen (Inst); ASCO (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); Bristol-Myers Squibb (Inst); Dracen (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MediLink Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst)
Travel, Accommodations, Expenses - DAVA Oncology; Genentech/Roche
 
Balazs Halmos
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Novartis; Nuvalent, Inc.; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Forward (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst); Tesaro/GSK (Inst)
 
Catherine Shu
Consulting or Advisory Role - AstraZeneca; EMD Serono; Genentech/Roche; Janssen
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Helena Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Bristol-Myers Squibb/Roche; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Orion Clinical; Taiho Oncology; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ABION; Allyst; ArriVent Biopharma; ArriVent Biopharma; AstraZeneca; Aviston; Bayer; Black Diamond Therapeutics; BlossomHill Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Merus; Novartis; PineTree; Regeneron; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Johnson & Johnson/Janssen; Regeneron; Spectrum Pharmaceuticals